A carregar...
Design of small molecules that compete with nucleotide binding to an engineered oncogenic KRAS allele
RAS mutations are found in 30% of all human cancers, with KRAS the most frequently mutated among the three RAS isoforms (KRAS, NRAS, HRAS). However, directly targeting oncogenic KRAS with small molecules in the nucleotide-binding site has been difficult due to the high affinity of KRAS for GDP and G...
Na minha lista:
| Publicado no: | Biochemistry |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5960803/ https://ncbi.nlm.nih.gov/pubmed/29313669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.biochem.7b01113 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|